Evidence map›Paper›PMID 42776828›Full record

ReviewHematology reports2026

Metallothionein Isoforms in Acute Myeloid Leukemia: Roles in Survival, Differentiation, and Stress Adaptation.

Shinichiro Takahashi

Abstract readReview
In one paragraph

Review in Hematology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Shinichiro TakahashiDivision of Laboratory Medicine, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, 1-15-1 Fukumuro, Miyagino-ku, Sendai 983-8536, Miyagi, Japan.ORCID 0000-0003-0011-6065

Funding

Ministry of Education, Culture, Sports, Science and Technology 25K10718
6 · The paper itself

Abstract

Metallothioneins (MTs) are cysteine-rich metal-binding proteins traditionally recognized for their roles in metal homeostasis and antioxidant defense. Recent studies have revealed broader and functionally diverse roles of MT isoforms in acute myeloid leukemia (AML). This review summarizes current evidence regarding MT-mediated regulation of leukemic cell survival, differentiation, and therapy-associated stress adaptation. MT1 family members, particularly MT1X and MT1G, have been associated with proliferation, chemoresistance, and differentiation blockade in specific experimental contexts, whereas MT2A and MT3 exhibit tumor-suppressive effects in selected AML models. MT isoforms also participate in oxidative stress adaptation and redox regulation, including responses to azacitidine, doxorubicin, and ferroptotic stress. However, the available evidence is derived largely from cell-line studies, selected molecular subtypes, transcriptomic analyses, and limited primary-patient datasets. Accordingly, isoform-specific MT functions should be interpreted as context-dependent rather than uniformly applicable across AML. Further validation in independent primary AML cohorts and genetically defined subtypes is required to establish their clinical utility as biomarkers or therapeutic targets.

Indexed as

acute myeloid leukemiadrug resistanceepigenetic regulationisoform-specific regulationmetallothioneinsredox homeostasisstress adaptation

Identifiers

PMID42776828
PMCPMC13600175

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.